Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27794127 | 0.84 | ALDH1A1 (0.51) | ALDH1A1BAZ2BBAZ2AGAALMNA | |
| SCHEMBL27915046 | 0.82 | ALDH1A1 (0.52) | ALDH1A1BAZ2BBAZ2AGAALMNA | |
| SCHEMBL70354 | 0.79 | BAZ2B (0.71) | ALDH1A1BAZ2BBAZ2AGAALMNA | |
| SCHEMBL1969597 | 0.79 | TDP1 (0.51) | GAA | |
| SCHEMBL25567051 | 0.78 | CREBBP (0.58) | ALDH1A1GAAKMT2A | |
| SCHEMBL19008981 | 0.78 | ALDH1A1 (0.34) | ALDH1A1BAZ2BBAZ2A | |
| SCHEMBL279718 | 0.77 | CCNC (0.43) | ALDH1A1KMT2A | |
| SCHEMBL23952006 | 0.76 | ALDH1A1 (0.54) | ALDH1A1GAALMNAMAPK1MEN1 | |
| SCHEMBL2661552 | 0.75 | ALDH1A1 (0.69) | ALDH1A1BAZ2BBAZ2AGAALMNA | |
| SCHEMBL162449 | 0.75 | BAZ2B (0.56) | ALDH1A1BAZ2BBAZ2AGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4155293-B1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-112533581-B | PRC1 inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2024-08-30 | — | — | CN | disclosed |
| EP-3813784-B1 | PRC1 INHIBITORS AND PRC1 INHIBITORS FOR USE IN METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
| EP-4155293-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents of The University of Michigan (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
| US-9758509-B2 | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758509-B2 | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| CN-101218234-B | Phenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2011-12-14 | — | — | CN | disclosed |
| EP-1912979-B1 | PHENYL-{3-(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
| CN-101218234-A | Phenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1912979-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006123257-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | ALDH1A1 1903/4885BAZ2B 8/4885BAZ2A 5/4885 |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | ALDH1A1 898/4885BAZ2B 295/4885BAZ2A 256/4885 |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | ALDH1A1 1903/4885BAZ2B 8/4885BAZ2A 5/4885 |
| US-20200039963-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | ALDH1A1 1903/4885BAZ2B 8/4885BAZ2A 5/4885 |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | ALDH1A1 1903/4885BAZ2B 8/4885BAZ2A 5/4885 |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | GRM5, GRIK5, GRM2 | ALDH1A1 4261/4885BAZ2B 1559/4885BAZ2A 1556/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | ALDH1A1 3479/4885BAZ2B 1107/4885BAZ2A 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.